|Marek L. Kowalski, Tomasz Gwardys, Jarosław Wlazłowski, Iwona Ligenza, Anna Stańczyk|
Inhalation therapy with disodium cromoglicate (DSCG) exerts anti-inflammatory effects that support its application in bronchial asthma. Previous studies demonstrated that DSCG reduced cough accompanying common cold, malignancies and that related with the angiotensin converting enzyme inhibitors. This study was aimed to evaluate effects of inhaled DSCG on cough and other symptoms of acute respiratory infection in children.
The double blind, placebo-controlled study included 74 children, aged 5 to 15, demonstrating symptoms of acute airway infection. Disodium cromoglicate was applied 4 times a day along with appropriate routine therapy. There were apparent differences in the intensity of infection symptoms during the second week of infection. Based on data from patient diaries, cough was remarkably attenuated in children treated with DSCG (p<0.05) as compared with placebo group. Further, cough intensity in the DSCG group was attenuated also according to physician evaluations.
The study indicates that inhaled DSCG attenuates cough symptoms and accelerates recovery from other symptoms of acute respiratory infection in children.
Alergia Astma Immunologia, 2001, 6(3), 159-163
keywords: kromoglikan dwusodowy, ostre infekcje, leczenie, dzieci, kaszel, disodium cromoglicate, DSCG treatment of respiratory infections, children, cough
pages: from 159 to 163
|estimated time of download (78 kB)|